Skip to main content
All lobbying filings

SOLVENTUM CORPORATION

Lobbying for SOLVENTUM CORPORATION

 Filing 3rd Quarter - Report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 20, 2025
Expenses
$140,000.00
What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Utah

Official filing document

 Lobbyists on this filing 1
  • MATTHEW JACKSON New on this filing
    Previously held: U.S. House: Chief of Staff, Rep. Bourdeaux; Leg. Dir, Rep. Bourdeaux; Leg. Asst, Rep. Bourdeaux; Leg. Corres., Rep. Rouda; Leg. Asst, Rep. Rouda; Staff Asst, Rep. Gomez; Intern, Rep. Gomez; Intern, Rep. Crowley; Intern, Rep. McGovern.

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 7
  • Centers For Medicare and Medicaid Services (CMS)
  • Defense, Dept of (DOD)
  • Environmental Protection Agency (EPA)
  • Health & Human Services, Dept of (HHS)
  • HOUSE OF REPRESENTATIVES
  • SENATE
  • Veterans Affairs, Dept of (VA)

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 1
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
 Lobbying activity 5
Veterans

Issues related to Veterans Administration and Veterans Health Administration policy, procurement, and contracting processes for medical technology.

Health Issues

-Issues related to regulation of Ethylene Oxide (EtO). -Issues related to access to sterilization capacity for medical technologies. -Medicare and Medicaid payment quality programs and policies, including healthcare associated complications, readmissions, payment bundling, potentially avoidable events, quality outcomes, transparency, telehealth, health equity, social determinants of health, maternal mortality, risk adjustment, Medicare Advantage, value-based payment policies, and Medicare and Medicaid data. -VA provider coding system modernization. -Implementation of the Patient Protection and Affordable Care Act (PL 111-148). -Implementation of the Helping Hospitals Improve Patient Care Act 21st Century Cures Act (PL 114-255). -Regulations and legislation related to International Classification of Diseases, version 10 (ICD-10). -Healthcare Outcomes Act. -Issues related to the use of Artificial Intelligence. -Issues related to H.R. 1 implementation (One Big Beautiful Bill). -Issues related to CY 2026 Home Health Prospective Payment System (HH PPS) Rate Update and DMEPOS.

Medicare/Medicaid

-Medicare and Medicaid payment quality programs and policies, including healthcare associated complications, readmissions, payment bundling, potentially avoidable events, quality outcomes, transparency, telehealth, health equity, social determinants of health, maternal mortality, risk adjustment, Medicare Advantage, value-based payment policies, and Medicare and Medicaid data. -VA provider coding system modernization. -Implementation of the Patient Protection and Affordable Care Act (PL 111-148). -Implementation of the Helping Hospitals Improve Patient Care Act 21st Century Cures Act (PL 114-255). -Regulations and legislation related to International Classification of Diseases, Version 10 (ICD-10). -Healthcare Outcomes Act. -Issues related to the use of Artificial Intelligence. -Issues related to H.R. 1 implementation (One Big Beautiful Bill). -Issues related to CY 2026 Home Health Prospective Payment System (HH PPS) Rate Update and DMEPOS.

Defense

-Issues related to Department of Defense policy, procurement, and contracting processes for medical technology. -Issues related to H.R. 1 implementation (One Big Beautiful Bill).

Trade (domestic/foreign)

-Issues related to domestic and global medical supply chain resilience. -Tariff issues generally. -Issues related to the 232 investigation of imports of Personal Protective Equipment, Medical Consumables, and Medical Equipment, Including Devices.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem